医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PeptiDream Announces Peptide Discovery Collaboration Agreement with Sanofi

2015年09月14日 PM03:54
このエントリーをはてなブックマークに追加


 

TOKYO

PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) today announced a multi-target discovery and optimization collaboration with Sanofi, Paris, France (“Sanofi”)(Euronext: SAN). Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocyclic/constrained peptides against multiple targets of interest selected by Sanofi. Sanofi will have the right to develop and commercialize all therapeutic peptides resulting from the collaboration. PeptiDream will receive an undisclosed upfront payment, research funding and will be eligible for payments associated with the achievement of certain preclinical and clinical development milestones. In addition, PeptiDream is eligible to receive royalties on sales of any products that arise from the collaboration.

We are very excited to begin collaborating with Sanofi, said Kiichi Kubota, CEO of PeptiDream Inc. Our unique PDPS platform continues to prove to be one of the best hit identification platforms, especially in targeting protein-protein interactions (PPIs). No other technology can create such a chemically and structurally diverse set of functional and developable leads in such a short period of time”.

In the past five years, PeptiDream has established funded discovery collaborations with Amgen, AstraZeneca, Bristol-Myers-Squibb, Eli Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck, as well as a strategic collaboration with Ipsen, all of which are actively progressing identified hits toward the clinic. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb and Novartis.

About PeptiDream Inc.

In the past five years, PeptiDream has established funded discovery collaborations with many leading pharmaceutical companies, such as Amgen, AstraZeneca, Bristol-Myers-Squibb, Eli Lilly, GlaxoSmithKline, Novartis, Merck, Mitsubishi Tanabe, Daiichi Sankyo, as well as a strategic collaboration with Ipsen, all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb and Novartis.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150913005124/en/

CONTACT

Enquiries:
PeptiDream Inc.
Patrick C Reid,
+81-3-5790-9991 (Tokyo)
p-reid@peptidream.com
http://www.peptidream.com/en/

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • SpeeDx Receives CARB-X Funding to Develop Rapid Point-of-Care Diagnostic
  • エアロバイオティクス、世界的医療投資会社のビボ・キャピタルが主導したグロース・エクイティ資金調達で2500万ドルを確保
  • Aerobiotix获2,500万美元的成长性股权融资,由全球医疗保健投资公司维梧资本领投
  • Mary Kay Unveils Skin Health Grants, Breakthrough Retinol Research at 2021 Society for Investigative Dermatology Conference
  • LianBio Appoints Yizhe Wang, Ph.D., as Chief Executive Officer